TCRT Key Statistics, Chart & Performance
The current stock price of TCRT is 3.28 USD. In the past month the price decreased by -7.87%. In the past year, price increased by 60%.
TCRT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About TCRT
Company Profile
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Fort Lauderdale, Florida and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The firm is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The firm has not generated any revenues.
Company Info
ALAUNOS THERAPEUTICS INC
501 E Las Olas Blvd, Suite 300
FORT LAUDERDALE FLORIDA US
Employees: 1
Phone: 13463554099
ALAUNOS THERAPEUTICS INC / TCRT FAQ
What does ALAUNOS THERAPEUTICS INC do?
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Fort Lauderdale, Florida and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The firm is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The firm has not generated any revenues.
Can you provide the latest stock price for ALAUNOS THERAPEUTICS INC?
The current stock price of TCRT is 3.28 USD. The price increased by 1.55% in the last trading session.
Does TCRT stock pay dividends?
TCRT does not pay a dividend.
What is the ChartMill rating of ALAUNOS THERAPEUTICS INC stock?
TCRT has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for ALAUNOS THERAPEUTICS INC?
ALAUNOS THERAPEUTICS INC (TCRT) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for ALAUNOS THERAPEUTICS INC?
ALAUNOS THERAPEUTICS INC (TCRT) currently has 1 employees.
TCRT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to TCRT. When comparing the yearly performance of all stocks, TCRT is one of the better performing stocks in the market, outperforming 93.1% of all stocks.
TCRT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TCRT. While TCRT seems to be doing ok healthwise, there are quite some concerns on its profitability.
TCRT Financial Highlights
Over the last trailing twelve months TCRT reported a non-GAAP Earnings per Share(EPS) of -2.29. The EPS decreased by -14.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -108.08% | ||
| ROE | -143.6% | ||
| Debt/Equity | 0 |